Have any questions? 706-721-6582 or cts@augusta.edu
- ALKS 4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)
Clinical Trial
ALKS 4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)
This is a Phase 1/2 study and will be conducted in 2 phases. The drugs ALKS 4230 and Pembrolizumab will be used to determine the recommended dosing and study side effects. As well as study the effect the drugs have on solid tumors, in both independent use of combined usage.
Eligibility Criteria
- At least 18 years old. Have a solid tumor that is resistant to some or all of the available standard treatments, or for which no standard treatment is available.
RESEARCH. INNOVATION. DISCOVERY.